1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Pennsylvania >
  6. SERB Pharmaceuticals Acquires BTG Specialty Pharmaceuticals

M&A Deal Summary

SERB Pharmaceuticals Acquires BTG Specialty Pharmaceuticals

On December 1, 2020, SERB Pharmaceuticals acquired medical products company BTG Specialty Pharmaceuticals from Boston Scientific for 800M USD

Acquisition Highlights
  • This is SERB Pharmaceuticals’ 1st transaction in the Medical Products sector.
  • This is SERB Pharmaceuticals’ largest (disclosed) transaction.
  • This is SERB Pharmaceuticals’ 1st transaction in the United States.
  • This is SERB Pharmaceuticals’ 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2020-12-01
Target BTG Specialty Pharmaceuticals
Sector Medical Products
Buyer(s) SERB Pharmaceuticals
Sellers(s) Boston Scientific
Deal Type Divestiture
Deal Value 800M USD

Target

BTG Specialty Pharmaceuticals

Gladwyne, Pennsylvania, United States
BTG Specialty Pharmaceuticals develops, manufactures, and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

SERB Pharmaceuticals

Luxembourg, Luxembourg
Category Company
Founded 1951
Sector Life Science
Employees390
DESCRIPTION

SERB Pharmaceuticals is an independent niche specialty pharma company focused on niche branded prescription medicines. The company has a strong focus on therapeutic areas such as critical and emergency care, neurology, diagnostics and endocrinology. SERB Pharmaceuticals was founded in 1951 and is based in Luxembourg.

DEAL STATS #
Overall 1 of 3
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 2
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 3
Year: 2020 M&A 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-13 Wellstat Therapeutics - Vistogard and Xuriden

Rockville, Maryland, United States

Wellstat Therapeutics's Vistogard and Xuriden provides emergency treatment for adult and pediatric patients with hereditary orotic aciduria (HOA)[ii], an ultra-rare, orphan genetic disorder associated megaloblastic anemia as well as failure to thrive, developmental delay, epilepsy, susceptibility to infection, and orotic acid crystals in the urine.

Buy -

Seller(S) 1

SELLER

Boston Scientific

Marlborough, Massachusetts, United States
Category Company
Founded 1979
Sector Medical Products
Employees48,000
Revenue 16.7B USD (2024)
DESCRIPTION
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.
Entrance to Boston Scientific's corporate headquarters in Marlborough, Massachusetts.

Boston Scientific is a medical technology company that offers products and technologies used to diagnose and treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. Boston Scientific was founded in 1979 and is based in Marlborough, Massachusetts.

DEAL STATS #
Overall 6 of 6
Sector: Medical Products M&A 4 of 4
Type: Divestiture M&A Deals 5 of 5
State: Pennsylvania M&A 1 of 1
Country: United States M&A 6 of 6
Year: 2020 M&A 2 of 2
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-21 Farapulse

Menlo Park, California, United States

Farapulse is a developer of a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. Farapulse was founded in 2012 and is based in Menlo Park, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-03 Lumenis Surgical Business

Yokneam, Israel

Lumenis' Surgical Business includes premier laser systems, fibers, and accessories used for urology and otolaryngology procedures.

Buy $1.1B
Mergr

Solution for

Product

Company

Legal